STMN2 and frontotemporal dementia: Given that the STMN2 cryptic exon has been proposed as biomarkers for ALS and FTD13,52, our findings raise the possibility that the MNAT1 cryptic exon may similarly serve as a potential biomarker for neurodegenerative disorders associated with TDP-43 proteinopathy, such as ALS and FTD.